The Alzheimer’s gene overactivates brain cells years before memory loss begins
Before a single memory slips, something has already gone wrong deep in the brain. Mice carrying the most dangerous genetic variant for Alzheimer’s have smaller, chronically overexcited neurons — and researchers have…
Alzheimer’s doesn’t start with forgetting. It starts decades earlier, quietly, in regions of the brain where cells begin to malfunction long before a doctor could detect anything wrong. The APOE4 gene is the single strongest known genetic risk factor for late-onset Alzheimer’s disease. One copy meaningfully raises risk; two copies can increase it tenfold or more. But exactly how APOE4 damages the brain has remained frustratingly unclear.
New research in mice pins down a concrete mechanism. Hippocampal neurons — the cells at the core of memory formation — were noticeably smaller in APOE4 mice than in animals without the variant. More strikingly, they were hyperexcitable: firing too easily, too often, in patterns that resemble epileptic activity and accelerated cellular aging. Crucially, this was already happening before any symptoms of dementia had developed.
A protein switch that changes the picture
The researchers then targeted a specific neuronal protein involved in regulating electrical excitability. By reducing its activity, they were able to partially reverse the hyperexcitability — the neurons calmed down. Whether this translates into actual protection against Alzheimer’s symptoms remains unproven; this is still mouse research. But the finding points toward a therapeutic angle that is entirely separate from the amyloid and tau strategies that have dominated — and largely disappointed — the field for decades.
The broader picture is both unsettling and intriguing. Unsettling, because it implies that the biological consequences of carrying APOE4 are already unfolding long before any diagnosis is possible. Intriguing, because an early biological signal is also an early intervention point. If hyperexcitability is a genuine precursor to Alzheimer’s, it could theoretically serve as a biomarker — something measurable that flags elevated risk before damage becomes irreversible.
The problem of timing
This is precisely where Alzheimer’s research has been stuck for years. The disease starts too early to catch at a moment when intervention still meaningfully changes the outcome. Drug after drug has failed in clinical trials — possibly because patients were already too far along. The question, then, is not just whether you can influence a mechanism, but when. And whether it is realistic to intervene early enough in APOE4 carriers to prevent the silent accumulation of damage before it becomes something irreversible.